Jiaomeng Pan

Jiaomeng Pan

Auto-generated profile, based on publicly available information

Jiaomeng Pan

Zhongshan Hospital 8

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 May 2024 in Science
Verified
Journal Article
Closed access
JMJiaqiang Ma
Jiaqiang Ma
YWYing Cheng Wu
Ying Cheng Wu
LMLifeng Ma
Lifeng Ma
XYXupeng Yang
Xupeng Yang
TZTiancheng Zhang
Tiancheng Zhang
QGQiang Gao
Qiang Gao
B lymphocytes are essential mediators of humoral immunity and play multiple roles in human cancer. To decode the functions of tumor-infiltrating B cells, we generated a B cell blueprint encompassing single-cell transcriptome, B cell–receptor repertoire, and chromatin accessibility data across 20 different cancer types (477 samples, 269 patients). B cells harbored extraordinary heterogeneity and comprised 15 subsets, which could be grouped into two independent developmental paths (extrafollicular versus germinal center). Tumor types grouped into the extrafollicular pathway were linked with worse clinical outcomes and resistance to immunotherapy. The dysfunctional extrafollicular program was associated with glutamine-derived metabolites through epigenetic-metabolic cross-talk, which promoted a T cell–driven immunosuppressive program. These data suggest an intratumor B cell balance between extrafollicular and germinal-center responses and suggest that humoral immunity could possibly be harnessed for B cell–targeting immunotherapy.

24 July 2023 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
KRAS mutations are causally linked to protumor inflammation and are identified as driving factors in tumorigenesis. Here, using multiomics data gathered from a large set of patients, we showed that KRAS mutation was associated with a specific landscape of alternative mRNA splicing that connected to myeloid inflammation in intrahepatic cholangiocarcinoma (iCCA). Then, we identified a negative feedback mechanism in which the upregulation of interleukin 1 receptor antagonist (IL1RN)-201/203 due to alternative splicing confers vital anti-inflammatory effects in KRAS-mutant iCCA. In KRAS-mutant iCCA mice, both IL1RN-201/203 upregulation and anakinra treatment ignited a significant antitumor immune response by altering neutrophil recruitment and phenotypes. Furthermore, anakinra treatment synergistically enhanced anti–PD-1 therapy to activate intratumoral GZMB+ CD8+ T cells in KRAS-mutant iCCA mice. Clinically, we found that high IL1RN-201/203 levels in patients with KRAS-mutant iCCA were significantly associated with superior response to anti–PD-1 immunotherapy. Significance: This work describes a novel inflammatory checkpoint mediated by IL1RN alternative splicing variants that may serve as a promising basis to develop therapeutic options for KRAS-mutant iCCA and other cancers. This article is featured in Selected Articles from This Issue, p. 2109

12 March 2025 in Hepatology
Verified
Journal Article
Closed access
JPJiaomeng Pan
Jiaomeng Pan
MZMao Zhang
Mao Zhang
DRDongning Rao
Dongning Rao
JMJunjie Ma
Junjie Ma
XSXia Shen
Xia Shen
JFJia Fan
Jia Fan
Background and Aims: Portal vein tumor thrombosis (PVTT), an indicator of clinical metastasis, significantly shortens hepatocellular carcinoma (HCC) patients’ lifespan, and no effective treatment has been established. We aimed to illustrate mechanisms underlying PVTT formation and tumor metastasis, and identified potential targets for clinical intervention. Approach and Results: Multi-omics data of 159 HCC patients (including 37 cases with PVTT) was analyzed to identify contributors to PVTT formation and tumor metastasis. In vitro and in vivo experiments were performed to confirm the critical role of carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase (CAD) in HCC metastasis. Metabolomics and transcriptomics techniques, single-cell RNA sequencing, combined with experimental verification were complemented to illustrate mechanisms underlying CAD induced pro-metastatic efficacy. Analysis of proteogenomic data of HCC cohort identified CAD as the key contributor to PVTT formation and tumor metastasis in HCC. Further experiments confirmed that high CAD expression could significantly promote HCC metastasis, and vice versa. Mechanistically, CAD manipulated de novo pyrimidine anabolism, leading to dihydroorotic acid (DHO) accumulation which directly bound to ubiquitination factor E4B (UBE4B). UBE4B subsequently regulated JAK1 ubiquitination and activated the NF-κB pathway to promote epithelial-mesenchymal transition (EMT) of HCC cells. Additionally, CAD generated an immunosuppressive milieu conducive to HCC metastasis by recruiting and reprogramming macrophages into a “pro-tumor” phenotype. Consequently, the metastatic capability of HCC was remarkably enhanced. Conclusion: Therapy targeting CAD may offer a promising approach to curb HCC metastasis by reducing tumor cells’ metastatic potential and also shifting the tumor microenvironment towards a less pro-metastatic state. Export

8 April 2026 in Cancer Discovery
Verified
Journal Article
Closed access
JLJian Lin
Jian Lin
CSChen Sang
Chen Sang
BXBin Xiang
Bin Xiang
XSXia Shen
Xia Shen
JZJunmei Zhao
Junmei Zhao
QGQiang Gao
Qiang Gao
Metabolic reprogramming within the tumor microenvironment impairs antitumor immunity and compromises the efficacy of immunotherapy. Through multi-omics-based metabolic subtyping in intrahepatic cholangiocarcinoma (iCCA), we identified a subgroup with the worst prognosis that demonstrates significant enrichment in both Cyclooxygenase/Arachidonic acid (COX/AA) metabolism and KRAS mutations. Mechanistically, KRAS mutation-mediated NF-κB pathway activation upregulates CXCL5 expression, thereby recruiting CXCR2+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) into the tumor microenvironment. Concurrently, KRAS mutation drives prostaglandin E2 (PGE2) production in tumor cells, and PGE2 in turn enhances arachidonic acid uptake and COX-2 expression in PMN-MDSCs, establishing an amplifying loop between tumor cells and PMN-MDSCs that exacerbates PGE2 production. PGE2 accumulation potently suppresses the antitumor activity of CD8+ T cells via prostaglandin E receptor 4 (EP4). Therapeutic targeting of the COX-2–PGE2–EP4 axis, combined with anti-PD-1 immunotherapy, demonstrates profound synergistic efficacy in both KRAS-mutant murine models and patient-derived tumor fragments harboring KRAS mutations.

16 September 2024
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.

12 December 2025
Verified
Other
Open access
MZMao Zhang
Mao Zhang
YHYingying Huang
Yingying Huang
JPJiaomeng Pan
Jiaomeng Pan
CSChen Sang
Chen Sang
YLYoupei Lin
Youpei Lin
QGQiang Gao
Qiang Gao
Supplementary Figure S1. Determination of AS index in iCCA. Supplementary Figure S2. Validation of distinct immune features in iCCA. Supplementary Figure S3. Detection of KRAS mutation associated indicators. Supplementary Figure S4. Exploration of the molecular mechanisms of IL1RN201/203 in iCCA. Supplementary Figure S5. Comparison between KRAS mutant (YAK) or KRASWT (YA) iCCA mice and functional validation of IL1RN-201/203. Supplementary Figure S6. Definition, validation and functional exploration of neutrophil clusters. Supplementary Figure S7. Effects of T cells, especially GZMB+ CD8+ T cells, on IL1RN-201/203 efficacy. Supplementary Figure S8. The roles of anti-PD1 Ab in KRASWT iCCA mice and anti-PD1 Ab plus anakinra in KRAS mutant iCCA mice. Supplementary Figure S9. Immunologic features of cancer patients with or without KRAS mutation.